Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy

INTRODUCTION: Docetaxel is an established standard therapy after osimertinib and platinum-based doublet chemotherapy (Pt-doublet) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor gene (EGFR) mutation. To facilitate future therapeutic deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Hidetoshi, Nishio, Makoto, Takahashi, Michiko, Tsuchiya, Hiroaki, Kasahara-Kiritani, Mami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499725/
https://www.ncbi.nlm.nih.gov/pubmed/37572265
http://dx.doi.org/10.1007/s12325-023-02616-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499725/
https://www.ncbi.nlm.nih.gov/pubmed/37572265
http://dx.doi.org/10.1007/s12325-023-02616-9

Ejemplares similares